Identification, in-vivo modelling and therapeutic targeting of superenhancer-driven oncogenes in Group 3 medulloblastoma.

Identification, in-vivo modelling and therapeutic targeting of superenhancer-driven oncogenes in Group 3 medulloblastoma.

We have agreed to donate £125,000 over 5 years towards improving understanding and treatment of the type of childhood brain tumour which took Oscar’s life.

OSCARs PBTC part-funds a researcher based at the world-renowned Institute of Cancer Research, who carries out work, as part of an international and interdisciplinary team, led by Professor Louis Chesler.

Medulloblastoma is the most common malignant brain tumour in children and causes 10% of cancer deaths. Large studies of tumour-tissue have identified four subgroups of medulloblastoma in patients, but only children with the two least aggressive subgroups have new treatment options. For those children with aggressive, “Group 3″ tumours, survival is dismal and treatment is devastating.

Professor Chesler is working with a team from Germany and the USA to study Group 3 medulloblastoma. The team will be analysing the genome in medulloblastoma tumour cells while also working on new ways to test drugs for this tumour type.

If successful, the research could, for the first time, reveal how these tumours are wired. This could mean that new drugs to treat this tumour type are delivered to the clinic within five years.